Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Plasma dihydroxyphenylalanine (DOPA) is independent of sympathetic activity in humans

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A totally new system is needed for drug research and development

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Patients not patents: Drug research and development as a public enterprise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of coronary heart disease or heart failure using high-sensitivity cardiac troponin T: a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Familial hypercholesterolaemia: cholesterol efflux and coronary disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ectopic eruption of the second premolar: an analysis of four different treatment approaches

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
To clarify the origin of plasma DOPA (3,4-Dihydroxyphenylalanine), the relationship between plasma DOPA and acute or chronic changes in sympathetic activity has been studied. Plasma DOPA and noradrenaline (NA) concentrations were measured by reverse-phase high-performance liquid chromatography with electrochemical detection. Administration of clonidine to healthy men decreased plasma NE markedly compared to no drug. Plasma DOPA decreased slightly but significantly with time, but values were identical after clonidine compared to no drug. Baseline plasma NE concentrations were significantly reduced in diabetic patients with autonomic neuropathy compared to diabetics without neuropathy, whereas baseline plasma DOPA concentrations were similar in the three groups investigated: 6.55 (5.03-7.26, median [interquartile range], n = 8) nmol l-1 in diabetics with neuropathy, 7.41 (5.79-7.97, n = 8) nmol l-1 in diabetics without neuropathy, and 6.85 (5.58-7.36, n = 8) nmol l-1 in controls. No relationship was obtained between baseline values of plasma NE and plasma DOPA. Plasma DOPA did not change in the upright position, whereas plasma NE increased significantly. Our results indicate that plasma DOPA is not related to sympathetic activity and may be of non-neuronal origin.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Investigation
Vol/bind19
Udgave nummer6
Sider (fra-til)514-7
Antal sider4
ISSN0014-2972
StatusUdgivet - dec. 1989

ID: 40238347